These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 8530590)

  • 1. Evidence of a distinct derangement of opioid tone in hyperinsulinemic patients with polycystic ovarian syndrome: relationship with insulin and luteinizing hormone secretion.
    Lanzone A; Fulghesu AM; Cucinelli F; Ciampelli M; Caruso A; Mancuso S
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3501-6. PubMed ID: 8530590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of ovarian steroids in the opioid-mediated reduction of insulin secretion in hyperinsulinemic patients with polycystic ovary syndrome.
    Guido M; Pavone V; Ciampelli M; Murgia F; Fulghesu AM; Apa R; Caruso A; Mancuso S; Lanzone A
    J Clin Endocrinol Metab; 1998 May; 83(5):1742-5. PubMed ID: 9589685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness of a somatostatin analogue in lowering luteinizing hormone and insulin-stimulated secretion in hyperinsulinemic women with polycystic ovary disease.
    Fulghesu AM; Lanzone A; Andreani CL; Pierro E; Caruso A; Mancuso S
    Fertil Steril; 1995 Oct; 64(4):703-8. PubMed ID: 7672138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term naltrexone treatment reduces the exaggerated insulin secretion in patients with polycystic ovary disease.
    Fulghesu AM; Lanzone A; Cucinelli F; Caruso A; Mancuso S
    Obstet Gynecol; 1993 Aug; 82(2):191-7. PubMed ID: 8336863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polycystic ovary syndrome: relationship between insulin sensitivity, sex hormone levels and ovarian stromal blood flow.
    Loverro G; Vicino M; Lorusso F; Vimercati A; Greco P; Selvaggi L
    Gynecol Endocrinol; 2001 Apr; 15(2):142-9. PubMed ID: 11379011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of long-term naltrexone treatment on growth hormone and insulin secretion in hyperandrogenic and normal obese patients.
    Villa P; Fulghesu AM; De Marinis L; Valle D; Mancini A; Pavone V; Caruso A; Lanzone A
    Metabolism; 1997 May; 46(5):538-43. PubMed ID: 9160821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of opioid blockade on insulin and growth hormone (GH) secretion in patients with polycystic ovary syndrome: the heterogeneity of impaired GH secretion is related to both obesity and hyperinsulinism.
    Villa P; Valle D; Mancini A; De Marinis L; Pavone V; Fulghesu AM; Mancuso S; Lanzone A
    Fertil Steril; 1999 Jan; 71(1):115-21. PubMed ID: 9935127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of insulin secretion on the ovarian response to exogenous gonadotropins in polycystic ovary syndrome.
    Fulghesu AM; Villa P; Pavone V; Guido M; Apa R; Caruso A; Lanzone A; Rossodivita A; Mancuso S
    J Clin Endocrinol Metab; 1997 Feb; 82(2):644-8. PubMed ID: 9024269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioid blockade effect on insulin beta-cells secretory patterns in polycystic ovary syndrome. Oral glucose load versus intravenous glucagon bolus.
    Ciampelli M; Fulghesu AM; Guido M; Murgia F; Muzj G; Belosi C; Fortini A; Cento R; Lanzone A
    Horm Res; 1998; 49(6):263-8. PubMed ID: 9623517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential androgen response to adrenocorticotropic hormone stimulation in polycystic ovarian syndrome: relationship with insulin secretion.
    Lanzone A; Fulghesu AM; Guido M; Fortini A; Caruso A; Mancuso S
    Fertil Steril; 1992 Aug; 58(2):296-301. PubMed ID: 1321739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gonadotropin levels in women with polycystic ovary syndrome: their relationship to body weight and insulin levels.
    Tropeano G; Vuolo IP; Lucisano A; Liberale L; Barini A; Carfagna P; Caroli G; Menini E; dell'Acqua S
    J Endocrinol Invest; 1996 Mar; 19(3):139-45. PubMed ID: 8743278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naltrexone effect on pulsatile GnRH therapy for ovulation induction in polycystic ovary syndrome: a pilot prospective study.
    Fulghesu AM; Ciampelli M; Belosi C; Apa R; Guido M; Caruso A; Mancuso S; Lanzone A
    J Endocrinol Invest; 2001; 24(7):483-90. PubMed ID: 11508781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of opioid tone in the pathophysiology of hyperinsulinemia and insulin resistance in polycystic ovarian disease.
    Fulghesu AM; Ciampelli M; Guido M; Murgia F; Caruso A; Mancuso S; Lanzone A
    Metabolism; 1998 Feb; 47(2):158-62. PubMed ID: 9472963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome.
    Ciampelli M; Fulghesu AM; Cucinelli F; Pavone V; Ronsisvalle E; Guido M; Caruso A; Lanzone A
    Metabolism; 1999 Feb; 48(2):167-72. PubMed ID: 10024076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged opioid blockade with naltrexone and luteinizing hormone modifications in women with polycystic ovarian syndrome.
    Cagnacci A; Soldani R; Paoletti AM; Falqui A; Melis GB
    Fertil Steril; 1994 Aug; 62(2):269-72. PubMed ID: 8034071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity.
    Arroyo A; Laughlin GA; Morales AJ; Yen SS
    J Clin Endocrinol Metab; 1997 Nov; 82(11):3728-33. PubMed ID: 9360532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in luteinizing hormone and insulin secretion in polycystic ovarian syndrome.
    Fulghesu AM; Cucinelli F; Pavone V; Murgia F; Guido M; Caruso A; Mancuso S; Lanzone A
    Hum Reprod; 1999 Mar; 14(3):611-7. PubMed ID: 10221684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients.
    Genazzani AD; Santagni S; Rattighieri E; Chierchia E; Despini G; Marini G; Prati A; Simoncini T
    Gynecol Endocrinol; 2014 Jun; 30(6):438-43. PubMed ID: 24601829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone.
    Eagleson CA; Gingrich MB; Pastor CL; Arora TK; Burt CM; Evans WS; Marshall JC
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4047-52. PubMed ID: 11095431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of luteinizing hormone and insulin on sex steroids and sex hormone-binding globulin in the polycystic ovarian syndrome.
    Buyalos RP; Geffner ME; Watanabe RM; Bergman RN; Gornbein JA; Judd HL
    Fertil Steril; 1993 Oct; 60(4):626-33. PubMed ID: 8405515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.